Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AETIONOMY

Financiado

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases fo...

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer ov... ver más

31/12/2018

UCB

18M€

Presupuesto del proyecto: 18M€

Líder del proyecto

UCB BIOPHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 14 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-12-31 No tenemos la información de la convocatoria

0% 100%

14 Participantes

UCB

Lider

FUNDACIO BARCELONABETA BRAIN...

N.D. | Participante

CONSORCI INSTITUT D INVESTIG...

N.D. | Participante

UKB

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLUBIODEM Fluid Biomarkers for Neurodegenerative Dementias 2M€ Cerrado

CTQ2015-68380-R NUEVAS MOLECULAS MULTIDIANA Y TERANOSTICAS PARA EL DIAGNOSTI... 155K€ Cerrado

JCI-2010-06938 COMPUTATIONAL INTELLIGENCE IN NEUROINFORMATICS: ADVANCES ON... 101K€ Cerrado

PID2020-115961RB-C31 ESTUDIO EXPERIMENTAL DEL FLUJO DE LIQUIDO CEFALORRAQUIDEO EN... 169K€ Cerrado

FJC2021-047583-I Identification of targets and search for new drugs for the t... 65K€ Cerrado

BIO2013-48222-R DESARROLLO DE NUEVAS ESTRATEGIAS TERAPEUTICAS, BASADAS EN PH... 288K€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2014-01-01
Fecha Fin: 2018-12-31

Líder del proyecto

UCB BIOPHARMA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 18M€

Descripción del proyecto IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and (II) the focused application of this pipeline to derive clinically significant mechanistic taxonomies of neurodegenerative diseases. These taxonomies will represent multi-scale structural and functional understanding of the causal mechanisms of and possible treatments in PD and AD. In particular, knowledge integration about neural substrates and their functional correlates will be generated through a pipeline that co-ordinates:I. the manual knowledge acquisition of mechanistic neurological knowledge from clinical experts,II. the semi-automated calculation of functional indices derived from clinical examination datasets, neuroradiological images and clinical and experimental investigation results,III. the large-scale acquisition of further evidence about functional relationships between knowledge created in i & ii by mining electronic health records and the literature,IV. the automated detection of significant correlations inferred from knowledge derived from steps i to iii above.To that end, AETIONOMY has assembled a seasoned consortium of expert clinicians and scientists to build upon (A) previous work within the consortium, which comprises unpublished and published work (ontologies such as ADO, the Alzheimer´s Disease Ontology, in press in Alzheimer´s & Dementia”; disease models such as the comprehensive CellDesigner model for PD build by partner LCSB) and (B) considerable public domain resources generated by large international communities (e.g. the Neuroscience Information Framework), and (C) results from ongoing IMI projects (e.g. DDMoRe, OpenPHACTS, eTRIKS, EMIF), providing a unique combination of tools and expertise to discover the core criteria that make for a good drug target and, in so doing, classify patients according to these criteria.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores